3 research outputs found
A Modified Method for Increasing Radiochemical Purity of I-125 for Radiopharmaceuticals
Iodine-125 (125I) is one of the radioisotopes widely used in radiopharmaceuticals for diagnosis and therapy of various cancers. Recent reports indicate that there has been shortages in the world supply of this radioiodine isotope. One of the absolute requirements good radiopharmaceuticals must meet is radiochemical purity, which generally has to be above 95 %, with an efficiency of over 90 %. The previous investigation shows that the radiochemical purity is low and does not meet the radiochemical requirement. In this work, we aim at improving the previous method by modifying the Jones reductor-based method. The modified method includes reduction and uniformization of Zn particle sizes, Zn particle compaction, and the performance of reduction process in a closed process flow. The Jones reductor converted impurities into products; in this case, iodate (IO3-) and periodate (IO4-) impurities were converted into iodide (I-), so that 125I product fulfills the radiochemical purity requirements and yielded high efficiency. In this investigation, the 125I previous product was, for the first time, improved with a radiochemical purity of 99.24 % and an efficiency of 97.98 %
Synthesis and Characterization of Poly(Amidoamine) Dendrimers Encapsulated 198Au Nanoparticles
Brachytherapy or internal radiotherapy is one of many methods used for treatment of cancer. This modality requires an agent with radionuclides that emits α or β particle with a proper energy. 198Au (99% β max = 0.96 MeV and t1/2 = 2.69 days) is one of radionuclides that has been considered to be effective for the above-mentioned purpose. The purpose of this research was to synthesis and characterize poly(amidoamine) (PAMAM) G3.0 dendrimers encapsulated 198Au nanoparticles as a new brachytherapy agent. PAMAM G3.0 dendrimers encapsulated 198Au nanoparticles was successfully synthesized by a bottom-up method using sodium borohydride as a reductor. Purification was then performed by a size exclusion chromatography in order to separate large Au nanoparticles that were formed outside the cavity of PAMAM G3.0 dendrimers. Prior to the synthesis of PAMAM G3.0 dendrimers encapsulated 198Au nanoparticles, the synthetic procedure was first established by using a non-radioactive Au. The PAMAM G3.0 dendrimers encapsulated Au nanoparticles produced was then characterized by using an UV-Vis spectroscopy, a transmission electron microscopy (TEM), particle size analyzer (PSA), and an atomic absorption spectroscopy (AAS). Characterization results revealed that PAMAM G3.0 dendrimers encapsulated Au nanoparticles that were prepared from a reaction mixture of PAMAM G3.0 dendrimers and Au HAuCl4 with mol ratio of 2.8, was found to be a proper formula. It produced PAMAM G3.0 dendrimers encapsulated Au nanoparticles with diameter of 1.743 nm, spheris, uniform and drug loading value of 26.34%. This formula was then used in synthesis using radioactive Au, 198Au. Characterization results of PAMAM G3.0 dendrimers encapsulated 198Au nanoparticles gave a radiochemical purity of 99.4% and zero charge. Received: 04 December 2012; Revised: 18 December 2012; Accepted: 20 December 201
Synthesis and Characterization of Poly(Amidoamine) Dendrimers Encapsulated 198Au Nanoparticles
Brachytherapy or internal radiotherapy is one of many methods used for treatment of cancer. This modality requires an agent with radionuclides that emits α or β particle with a proper energy. 198Au (99% β max = 0.96 MeV and t1/2 = 2.69 days) is one of radionuclides that has been considered to be effective for the above-mentioned purpose. The purpose of this research was to synthesis and characterize poly(amidoamine) (PAMAM) G3.0 dendrimers encapsulated 198Au nanoparticles as a new brachytherapy agent. PAMAM G3.0 dendrimers encapsulated 198Au nanoparticles was successfully synthesized by a bottom-up method using sodium borohydride as a reductor. Purification was then performed by a size exclusion chromatography in order to separate large Au nanoparticles that were formed outside the cavity of PAMAM G3.0 dendrimers. Prior to the synthesis of PAMAM G3.0 dendrimers encapsulated 198Au nanoparticles, the synthetic procedure was first established by using a non-radioactive Au. The PAMAM G3.0 dendrimers encapsulated Au nanoparticles produced was then characterized by using an UV-Vis spectroscopy, a transmission electron microscopy (TEM), particle size analyzer (PSA), and an atomic absorption spectroscopy (AAS). Characterization results revealed that PAMAM G3.0 dendrimers encapsulated Au nanoparticles that were prepared from a reaction mixture of PAMAM G3.0 dendrimers and Au HAuCl4 with mol ratio of 2.8, was found to be a proper formula. It produced PAMAM G3.0 dendrimers encapsulated Au nanoparticles with diameter of 1.743 nm, spheris, uniform and drug loading value of 26.34%. This formula was then used in synthesis using radioactive Au, 198Au. Characterization results of PAMAM G3.0 dendrimers encapsulated 198Au nanoparticles gave a radiochemical purity of 99.4% and zero charge. Received: 04 December 2012; Revised: 18 December 2012; Accepted: 20 December 201
